

1 **EXPLORATORY ASSESSMENT OF LEFT VENTRICULAR**  
2 **STRAIN-VOLUME LOOPS IN SEVERE AORTIC VALVE**  
3 **DISEASES**

4  
5  
6 HUGO G. HULSHOF, MSc<sup>1</sup>

7 ARIE P. VAN DIJK, MD PhD<sup>1</sup>

8 KEITH P. GEORGE, PhD<sup>2</sup>

9 MARIA T.E. HOPMAN, MD PhD<sup>1</sup>

10 DICK H.J. THIJSEN, PhD<sup>1,2</sup>

11 DAVID L. OXBOROUGH, PhD<sup>2</sup>

12  
13  
14  
15 <sup>1</sup>Radboud Institute for Health Sciences, Departments of Physiology and Cardiology, Radboud  
16 University Medical Center, Nijmegen, The Netherlands

17 <sup>2</sup>Research institute for Sport and Exercise Sciences, Liverpool John Moores University,  
18 Liverpool, United Kingdom

19  
20  
21 **Short title:** Cardiac strain-volume loops to identify pathology

22  
23  
24  
25 **Author for correspondence:**

26 Dr. David Oxborough, Research Institute for Sport and Exercise Sciences, Liverpool John  
27 Moores University, Tom Reilly Building, Byrom Street, L3 3AF, Liverpool, United  
28 Kingdom, Email: [D.L.Oxborough@ljmu.ac.uk](mailto:D.L.Oxborough@ljmu.ac.uk), Tel: 0151 904 6231, Fax: 0151 904 6230

29 **Key points summary**

- 30 • Severe aortic valve diseases represent common cardiac abnormalities that are associated  
31 with poor long-term survival.
- 32 • Prior to any reduction in left ventricular function, the left ventricle undergoes structural  
33 remodeling under the influence of a changing haemodynamic conditions.
- 34 • In this study, we combined temporal changes in LV structure (volume) to alterations in LV  
35 functional characteristics (strain,  $\epsilon$ ) into a  $\epsilon$ -volume loop, to provide novel insight into the  
36 haemodynamic cardiac consequences of aortic valve diseases in those with preserved LV  
37 ejection fraction.
- 38 • We showed that our novel  $\epsilon$ -volume loop and the specific loop characteristics provides  
39 additional insight in the functional and mechanical haemodynamic consequences of severe  
40 aortic valve diseases (with preserved LV ejection fraction).
- 41 • Finally we showed that the  $\epsilon$ -volume loop characteristics provide discriminative capacity  
42 compared to conventional measures of left ventricular function.

43

44 **ABSTRACT**

45 **Objectives.** The purpose of this study was to examine left ventricular (LV) strain ( $\epsilon$ )-volume  
46 loops to provide novel insight into the haemodynamic cardiac consequences of aortic valve  
47 stenosis (AS) and aortic valve regurgitation (AR).

48 **Methods.** 27 participants were retrospectively recruited: AR (n=7), AS (n=10) and controls  
49 (n=10). Standard transthoracic echocardiography was utilised to obtain apical 4 chamber  
50 images to construct  $\epsilon$ -volume relationships were assessed by: Early systolic  $\epsilon$  ( $\epsilon_{ES}$ ), slope of  
51  $\epsilon$ -volume relation during systole (Sslope), End-systolic peak  $\epsilon$  (peak  $\epsilon$ ), Diastolic uncoupling  
52 (systolic  $\epsilon$ -diastolic  $\epsilon$  at same volume) during early diastole (UNCOUP\_ED) and late diastole  
53 (UNCOUP\_LD). ROC-curves were used to determine the ability to detect impaired LV  
54 function.

55 **Results.** Whilst LV ejection fraction was comparable between groups, longitudinal peak  $\epsilon$  was  
56 similarly reduced compared to controls. In contrast,  $\epsilon_{ES}$  and Sslope were lower in both  
57 pathologies compared to controls ( $P<0.01$ ), but also different between AS and AR ( $P<0.05$ ).  
58 UNCOUP\_ED as UNCOUP\_LD were significantly higher in both patient groups compared to  
59 controls ( $P<0.05$ ). ROC-curves revealed that loop characteristics (AUC=0.99, 1.00, 1.00; all  
60  $P<0.01$ ) were better able than peak  $\epsilon$  (AUC=0.75, 0.89, 0.76;  $P=0.06$ ,  $<0.01$  and 0.08,  
61 respectively) and LV ejection fraction (AUC=0.56, 0.69, 0.69; all  $P>0.05$ ) to distinguish AS vs  
62 Controls, AR vs Controls and AS vs AR, respectively.

63 **Conclusions.** Temporal changes in  $\epsilon$ -volume characteristics provide novel insight into the  
64 haemodynamic cardiac impact of AS and AR. Contrary to traditional measures (i.e. ejection  
65 fraction, peak  $\epsilon$ ), these novel measures successfully distinguish between the haemodynamic  
66 cardiac impact of AS and AR.

67

68 **KEYWORDS:** Cardiovascular disease; cardiac strain; echocardiography; aortic valve  
69 disease; haemodynamic

70

71 **ABBREVIATIONS**

72 American Society of Echocardiography (ASE)

73 Aortic Valve Area (AVA)

74 Aortic valve stenosis (AS)

75 Aortic valve regurgitation (AR)

76 Cardiac output (CO)

77 Diastolic uncoupling during early diastole (UNCOUP\_ED)

78 Diastolic uncoupling during late diastole (UNCOUP\_LD)

79 Early systolic  $\epsilon$  ( $\epsilon_{ES}$ )

80 Heart rate (HR)

81 Left atrial (LA)

82 Left atrial diameter (LAdiam)

83 Left atrial end systolic volume (LAESV)

84 Left ventricular (LV)

85 Left ventricular end diastolic volume (LVEDV)

86 Left ventricular ejection fraction (LVEF)

87 Left ventricular end systolic volume (LVESV)

88 Linear slope during systole (Sslope)

89 Peak strain (peak  $\epsilon$ )

90 Region of interest (ROI)

91 Strain ( $\epsilon$ )

92 Stroke volume (SV)

93 Vena contracta (VC)

94 **INTRODUCTION**

95 Severe aortic valve stenosis (AS) and severe aortic valve regurgitation (AR) represent common  
96 cardiac abnormalities that are associated with poor long-term survival (Dujardin *et al.*, 1999;  
97 Carabello, 2008; Samad *et al.*, 2016). Current management of these conditions is based on serial  
98 echocardiographic assessment with current guidelines recommending valve replacement in case  
99 of symptoms or reduced left ventricle ejection fraction (LVEF) below 50% (Bonow *et al.*, 2008;  
100 Galli *et al.*, 2014). The inherent limitations and load dependency (Mangano *et al.*, 1980; Dong  
101 *et al.*, 1999) make LVEF a suboptimal marker to assess progression and status of AS and AR  
102 (Hachicha *et al.*, 2007; Galli *et al.*, 2014). Prior to any reduction in LVEF, the LV undergoes  
103 structural remodeling under the influence of an increased afterload in AS and a significant  
104 volume overload in AR (Bonow *et al.*, 2008; Maganti *et al.*, 2010; Kamperidis *et al.*, 2016).  
105 Temporally linking the changes in LV structure to alterations in functional characteristics of  
106 the LV may provide more detailed insight into the haemodynamic cardiac consequences of both  
107 aortic valve disease states.

108  
109 The introduction of speckle tracking techniques in echocardiography has allowed for the  
110 measurement of strain ( $\epsilon$ ) (Artis *et al.*, 2008; Dandel *et al.*, 2009; Mondillo *et al.*, 2011), which  
111 is a valid technique for assessment of LV deformation. Previous work has demonstrated a lower  
112 longitudinal (global or segmental) peak  $\epsilon$  in AS or AR patients with preserved LVEF (Delgado  
113 *et al.*, 2009; Smedsrud *et al.*, 2011; Adda *et al.*, 2012; Lavine & Al Balbissi, 2015). Nonetheless,  
114 marked overlap remained in longitudinal peak  $\epsilon$  between these disease states and healthy  
115 controls which is further limited by a single measurement of longitudinal peak  $\epsilon$  not reflecting  
116 the temporal changes throughout the cardiac cycle.

117

118 In this exploratory study, we adopted a novel approach to assess LV  $\epsilon$  across the cardiac cycle  
119 and subsequently relate these to simultaneous assessment of LV volume (Lord *et al.*, 2016;  
120 Oxborough *et al.*, 2016). This simultaneous assessment establishes the relative contribution of  
121 longitudinal  $\epsilon$  to volume changes throughout the cardiac cycle providing a  $\epsilon$ -volume loop.  
122 The  $\epsilon$ -volume loop can establish relative longitudinal strain's contribution to volume change in  
123 systole and diastole. Our previous work has demonstrated a similar  $\epsilon$  value for any given volume  
124 during diastole and systole in healthy individuals and athletes (Oxborough *et al.*, 2016),  
125 suggesting the presence of strong systolic-diastolic coupling. This observation suggests that  
126 longitudinal  $\epsilon$  is closely related during contraction (i.e. systole) or relaxation (i.e. diastole).  
127 Previously, it was found that upon alterations in cardiac load (Lord *et al.*, 2016), dissociation  
128 occurs between systolic and diastolic  $\epsilon$  at the same volume (i.e. uncoupling). Also in severe  
129 chronic valve disease, where differences are present in structural integrity and load alterations,  
130 uncoupling may be present. This measure, through combining functional and structural  
131 information, may therefore provide additional, novel insight into the haemodynamic cardiac  
132 consequences of AS and AR. Consequently, we aimed to determine whether traditional  
133 echocardiographic measures (e.g. LVEF and peak  $\epsilon$ ) and characteristics of the LV  $\epsilon$ -volume  
134 loop are different between healthy controls, patients with severe AS, and patients with severe  
135 AR. We hypothesise that, in contrast to traditional echocardiographic measures, temporal  
136 changes in the  $\epsilon$ -volume loop would provide data that could distinguish between the  
137 haemodynamic cardiac impact of AS (i.e. driven by increased afterload) and AR (i.e. driven by  
138 increased volume overload).

139

## 140 **METHODS**

141 *Ethical approval*

142 We received approval from the Radboud University Medical Center ethics committee to  
143 perform the proposed work (reference number 2015-1727) and in this process, informed  
144 consent from participants was received to perform data analysis as executed in the present  
145 study. This study conforms to the standards set by the latest revision of the Declaration of  
146 Helsinki.

147

#### 148 *Study population*

149 We retrospectively included 27 participants, consisting of severe AR (n=7; 45±10 years; 14%  
150 Female), severe AS (n=10; 47±11 years; 40% Female) and controls (n=10; 50±10 years; 50%  
151 Female), who underwent an echocardiographic assessment at the Radboud University Medical  
152 Center (Nijmegen). Participants were randomly selected from a database that includes  
153 echocardiographic data from patients that underwent echocardiography at the Department of  
154 Cardiology of the Radboud University Medical Center since 2009. We first identified subjects  
155 with chronic severe disease, utilizing the echocardiographic diagnosis of severe AS or severe  
156 AR documented by a cardiologist using the American Society of Echocardiography (ASE)  
157 guidelines for valve stenosis (Baumgartner *et al.*, 2009) and valve regurgitation (Lancellotti *et*  
158 *al.*, 2010). For severe AS, a cut off value for Aortic Valve Area of 1.0 cm<sup>2</sup> was used. For AR,  
159 a classification of severe was determined using a combination of qualitative and quantitative  
160 adjunctive parameters (Table 1) in accordance with international guidelines (Lancellotti *et al.*,  
161 2010). Participants were excluded if they had a history of coronary artery disease, the presence  
162 of LV regional wall motion abnormalities, an abnormal LVEF, co-existing mitral, pulmonic or  
163 tricuspid valve disease (greater than mild in severity) or any other documented cardiac  
164 pathology. After identifying eligible patients, a single researcher went through the list in  
165 chronological order (starting with the most recent measurements) and selected the participants  
166 from the list when the echocardiographic measurements: *i.* included all required images/planes,

167 and *ii.* achieved high quality imaging to ensure eligibility for our analysis. In this procedure,  
168 the researcher was blinded for health status and other subject characteristics. Before final  
169 inclusion, all participants that were selected by the researcher were verified (regarding in- and  
170 exclusion criteria and quality of the echocardiography data) by a single experienced cardiologist  
171 (AvD). Controls were selected in the absence of documented cardiovascular diseases,  
172 hypertension, history of cardiovascular medication and in the presence of normal cardiac  
173 function using the ASE guidelines for cardiac chamber quantification (Lang *et al.*, 2015).

174

#### 175 *Measurements*

176 Echocardiographic data was obtained using a Vivid E9 ultrasound machine (GE Medical  
177 System, Horton, Norway) with a 1.5-4 MHZ phased array transducer. The data was stored in  
178 raw DICOM format in a remote archive of the Department of Cardiology at the Radboud  
179 University Medical Center (Nijmegen). Data was analysed using commercially available  
180 software (EchoPac version 113.05, GE Medical, Horten, Norway).

181

#### 182 *2D Echocardiographic Assessment*

183 Echocardiographic images were acquired in accordance with the recommendations of the ASE  
184 (Lang *et al.*, 2015) by an experienced sonographer from the Radboudumc (Nijmegen) with the  
185 patient in the left lateral decubitus position. In addition to the measurements to determine valve  
186 disease severity, traditional structural and functional LV and left atrial (LA) parameters were  
187 calculated from appropriate images by a single operator with experience in echocardiographic  
188 imaging. LV linear dimensions and LA diameter (LA<sub>diam</sub>) were measured using 2-dimensional  
189 imaging from a parasternal long axis orientation and LV mass was calculated according to the  
190 ASE corrected Devereaux formula (Lang *et al.*, 2006). LV end diastolic volume (LVEDV), LV  
191 end systolic volume (LVESV), LVEF and LA end systolic volume (LAESV) were calculated



192 using Simpson's biplane method utilizing both apical four and two chamber orientations. Stroke  
193 volume (SV) was calculated by subtracting LVESV from LVEDV and cardiac output (CO) was  
194 calculated by multiplying SV and heart rate (HR).

195

#### 196 *2D Myocardial Speckle Tracking*

197 A LV focused apical four chamber view was used to assess simultaneous longitudinal  $\epsilon$  and LV  
198 volume. Images were optimized to ensure adequate endocardial delineation using gain,  
199 compression and reject. Frame-rates were maintained between 40 and 90 fps and a focal zone  
200 was positioned at mid-cavity to reduce the impact of beam divergence. Myocardial  $\epsilon$  and  
201 volume were assessed offline using dedicated software (EchoPac V113.05, GE Healthcare,  
202 Horton, Norway). A region of interest (ROI) was placed from the basal septum to the basal  
203 lateral wall of the LV enclosing the myocardium. The ROI was divided in six myocardial  
204 segments, providing segmental and global longitudinal  $\epsilon$ . Global longitudinal  $\epsilon$  was used for  
205 subsequent analysis.

206

#### 207 *$\epsilon$ -volume Loops*

208 Temporal longitudinal  $\epsilon$  values were exported to a spreadsheet (Excel, Microsoft Corp,  
209 Washington, US). Using cubic spline interpolation the global temporal longitudinal  $\epsilon$  values  
210 were divided in 300 points for systole and 300 points for diastole. For both systole and diastole  
211 the 300  $\epsilon$  values were then split into 5% increments of the cardiac cycle providing longitudinal  
212  $\epsilon$  values at 10 time points in systole and 10 time points in diastole. Concomitant time points for  
213 the  $\epsilon$  values were used in the same image and cardiac cycle to trace LV monoplane volumes to  
214 provide simultaneous  $\epsilon$  and volume values. For each patient a longitudinal  $\epsilon$ -volume loop was  
215 created after which a mean longitudinal  $\epsilon$ -volume loops for each group was calculated.

216

217 Using the individual  $\epsilon$ -volume loops a linear regression line and a polynomial of two orders  
218 were applied to both diastolic and systolic parts of the loop. This derived polynomial equation  
219 allowed the derivation of  $\epsilon$  at % increments of LVEDV. The longitudinal  $\epsilon$ -volume relationship  
220 was assessed by 1) Early systolic  $\epsilon$  ( $\epsilon_{ES}$ ), 2) linear slope of  $\epsilon$ -volume relation during systole  
221 (Sslope), 3) End-systolic peak  $\epsilon$  (peak  $\epsilon$ ), 4) Diastolic uncoupling (i.e difference systolic vs  
222 diastolic  $\epsilon$ ) during early filling (UNCOUP\_ED) and 5) Diastolic uncoupling during late diastole  
223 (UNCOUP\_LD) (fig. 1).

224

225  $\epsilon_{ES}$  was determined by calculating the volume at 90% of EDV, the resulting volume was then  
226 implemented in the formula of the polynomial regression line to calculate the matching systolic  
227  $\epsilon$  value at 90% of EDV. The Sslope was derived as the gradient of the linear regression line  
228 over the systolic phase of the  $\epsilon$ -volume loop. Longitudinal peak  $\epsilon$  was derived as the raw peak  
229  $\epsilon$  value from the longitudinal  $\epsilon$  data. UNCOUP\_ED and UNCOUP\_LD were calculated across  
230 the area between the systolic and diastolic polynomial curves. Using the same method as for  
231  $\epsilon_{ES}$  systolic and diastolic  $\epsilon$  values were calculated at 10% increments between 40 and 90% of  
232 EDV. By subtracting diastolic from systolic  $\epsilon$  the difference at each point was calculated. Based  
233 on individual LVEF the working range of the heart was determined, after which UNCOUP\_ED  
234 was calculated as the sum of the differences at the lowest 2/3 of increments of EDV in the  
235 working range of the heart, UNCOUP\_LD was calculated as the sum of the differences at the  
236 highest 1/3 increments of EDV in the working range of the heart. All data from individual loops  
237 were averaged across the cohort to provide peak values and  $\epsilon$ -volume loops for all three groups.  
238 Intra-user variability analysis revealed the following intra-class correlations for the loop  
239 characteristics:  $\epsilon_{ES}$  (ICC: 0.945,  $P < 0.001$ ), Sslope (ICC: 0.950,  $P < 0.001$ ), Peak\_ $\epsilon$  (ICC:  
240 0.831,  $P < 0.01$ ), UNCOUP\_ED (ICC: 0.779,  $P < 0.01$ ) and UNCOUP\_LD (ICC: 0.737,  $P < 0.05$ ).

241

242 *Statistical analysis*

243 The resulting data for each group is expressed as mean  $\pm$  standard deviation. Normality of data  
244 distribution was examined using a Kolmogorov-Smirnov test. In case non-Gaussian distribution  
245 was observed, log-transformation was applied after which the data was re-examined. A one-  
246 way sample ANOVA (IBM SPSS statistics version 22) was used to assess differences between  
247 groups for all parametric variables. Sex was compared using a Chi-square test. A P-value of  
248  $<0.05$  was considered significant. In case of significant differences between groups, a LSD Post  
249 Hoc analysis was applied to establish differences between pairwise group comparisons.  
250 Additionally we compared the loop characteristics within each group for sex related differences.  
251 To better understand the potential added value of the novel loop characteristics, a correlation  
252 between measures of the  $\epsilon$ -volume relationship was calculated with traditional measures of LV  
253 function (LVEF and peak  $\epsilon$ ) using the Pearson's bivariate correlation coefficient. Additionally  
254 we used ROC-curves to determine whether traditional (i.e. LVEF) and more novel (i.e. peak  $\epsilon$   
255 and our combined  $\epsilon$ -volume loop characteristics) markers of LV function can distinguish  
256 between healthy controls, AS and AR. Furthermore, we explored overlap in longitudinal peak  
257  $\epsilon$  between the 3 groups and compared overlap in 95% confidence intervals between groups for  
258 the newly derived characteristics in a figure. Finally, we performed a sub-analysis of controls  
259 (n=3), AS (n=3) and AR patients (n=3) to examine potential differences in the  $\epsilon$ -volume loop  
260 characteristics in the presence of comparable longitudinal peak  $\epsilon$  values.

261

262

## 263 **RESULTS**

264 There were no significant differences in age, weight, height, BSA or HR between all groups  
265 (Table 1). Structural parameters of the LV and LA, were significantly larger in AR compared

266 to AS and controls with no difference between controls and AS. We observed no differences in  
267 LVEF between groups.

268

269 *ε-volume loop (longitudinal)*. Longitudinal peak  $\epsilon$  was significantly lower in both pathologies  
270 compared to controls, but no difference was observed between AS and AR (Table 2). In  
271 contrast,  $\epsilon_{ES}$  and  $S_{slope}$  were lower in AR and AS compared to controls and AR  
272 demonstrating lower values compared to AS. UNCOUP\_ED and UNCOUP\_LD are  
273 significantly higher in both pathologies compared to controls, while no difference between AS  
274 and AR was present. No significant differences in the loop characteristics were observed  
275 between male and female participants within groups (all comparisons  $P>0.05$ ).

276

277 We observed a moderate and significant correlation between longitudinal peak  $\epsilon$  and  $\epsilon_{ES}$  ( $r=-$   
278  $0.464$   $P<0.05$ ) and  $S_{slope}$  ( $r=-0.675$   $P<0.01$ ). Peak  $\epsilon$  was not significantly correlated with  
279 UNCOUP\_ED or UNCOUP\_LD ( $P=0.380$  and  $0.201$ , respectively). There were no significant  
280 correlations between LVEF and any of the characteristics of the  $\epsilon$ -volume loop (all  $P>0.05$ ).

281

282 We found no discriminative capacity of LVEF for controls-AS (AUC=0.56;  $P=0.68$ ), controls-  
283 AR (AUC=0.69;  $P=0.13$ ) or AS-AR (AUC=0.69;  $P=0.21$ ). Whilst peak  $\epsilon$  did not distinguish  
284 between controls-AS (AUC=0.75;  $P=0.06$ ) or AS-AR (AUC=0.76;  $P=0.08$ ), differences were  
285 found between controls-AR (AUC=0.89 [1.000-0.718];  $P<0.01$ ). Finally, loop characteristics  
286 significantly distinguished groups for each comparison; controls-AS (AUC=0.99 [1.000-  
287 0.985];  $P<0.01$ ), controls-AR (AUC=1.00 [1.000-1.000];  $P<0.01$ ), and AS-AR (AUC=1.00  
288 [1.000-1.000];  $P<0.01$ ).

289

290 To better understand the ability of the  $\epsilon$ -volume loop values to characterise AS or AR, we have  
291 plotted the loop characteristics against peak  $\epsilon$  (Figure 3). The marked overlap of peak  $\epsilon$  values  
292 across the 3 groups (i.e. horizontal grey area) contrasts with the smaller overlap of Sslope,  $\epsilon_{ES}$ ,  
293 UNCOUP\_ED and UNCOUP\_LD (vertical grey area). Finally, distinct  $\epsilon$ -volume loop  
294 characteristics were present in subgroups of healthy controls, AS and AR who show comparable  
295 longitudinal peak  $\epsilon$  (Figure 4).

296

297

## 298 **DISCUSSION**

299 The purpose of this study was to examine whether characteristics of the LV  $\epsilon$ -volume loop, a  
300 novel method used here for the first time to link changes in cardiac  $\epsilon$  to alterations in LV cavity  
301 volume across the cardiac cycle, provides additional insight into the haemodynamic cardiac  
302 consequences of AS and AR. The key findings of the current study were that both valve  
303 pathologies lead to characteristic remodeling, with concentric remodeling of the LV in AS (i.e.  
304 pressure-overload) and eccentric remodeling in AR (i.e. volume-overload) (Bonow *et al.*,  
305 2008). Importantly, and despite significant remodeling, traditional measures of LV function  
306 provide no (LVEF) or little (peak  $\epsilon$ ) discriminative capacity between valve pathology *versus*  
307 controls or AS *versus* AR. In marked contrast, all characteristics of the  $\epsilon$ -volume loop were  
308 different between controls and valve pathology, whilst it successfully can distinguish between  
309 AS, AR and controls. More specifically, the initial change in  $\epsilon$  during systole (i.e.  $\epsilon_{ES}$ ) and  
310 the relation between  $\epsilon$  and volume (i.e. Sslope) were different between AS and AR.  
311 Furthermore, in the presence of comparable longitudinal peak  $\epsilon$ , characteristics of the  $\epsilon$ -volume  
312 loop differed among the 3 groups. These data suggest that the  $\epsilon$ -volume loop of the LV provides  
313 novel insight and additional discriminative capacity to understand functional consequences of  
314 (distinct) haemodynamic loading on the left ventricle in AS and AR.

315

316 Both AS and AR demonstrated significant left ventricular remodeling, either due to an increased  
317 afterload (i.e. AS) or increased volume (i.e. AR). In addition to structural remodeling, previous  
318 work revealed significant fibrosis in the endocardial layer in both AS and AR (Taniguchi *et al.*,  
319 2000; Rassi *et al.*, 2014). Given the longitudinal orientation of myocardial fibres, fibrosis of  
320 these fibres likely represents a key modulator of the reduction in longitudinal peak  $\epsilon$   
321 (Weidemann *et al.*, 2009; Rassi *et al.*, 2014). Despite the reduction in longitudinal peak  $\epsilon$ ,  
322 preserved LVEF was present in AS and AR. One potential explanation may relate to  
323 compensatory changes in circumferential  $\epsilon$ . An increase in circumferential  $\epsilon$  may contribute to  
324 preservation of ventricular function and LVEF (Carasso *et al.*, 2011; Iida *et al.*, 2012).  
325 Preserved LVEF and altered peak  $\epsilon$  may reflect compensatory remodeling, which are largely  
326 independent on the type of cardiac overload (pressure *versus* volume) and presence of  
327 remodeling (concentric *versus* eccentric).

328

329 To further understand the impact of valve pathology on the heart, we explored longitudinal  $\epsilon$ -  
330 volume loops and described differences in the temporal  $\epsilon$ -volume relationship across groups.  
331 First, during early systole, we observed smaller initial changes in longitudinal  $\epsilon$ . Whilst these  
332 changes were present in both disease states compared to controls, the attenuated  $\epsilon$ -responses  
333 were significantly larger in AR compared to AS. Presence of cardiac fibrosis may contribute to  
334 this observation, as fibrosis reflects myocyte degeneration, impairing ventricular contractility  
335 (Hein *et al.*, 2003). The altered relation between an increase in  $\epsilon$  alongside increases in volume  
336 (i.e.  $S_{slope}$ ) persists in both valve pathologies throughout the remainder of systole. Similar to  
337 early systolic changes, AR shows a further attenuation of this relation compared to AS. The  
338 larger attenuation of  $\epsilon_{ES}$  and  $S_{slope}$  in AR may be due to volume overload in AR, causing a  
339 further reduction in contractility due to loss of connection between myofibrils.

340

341 Controls show a close relation between changes in longitudinal  $\epsilon$  for a change in LV volume  
342 during diastole and systole. In marked contrast, AS and AR demonstrated dissociation between  
343 the diastolic *versus* systolic longitudinal  $\epsilon$  at any given volume change, indicating the presence  
344 of significant uncoupling between  $\epsilon$  and volume relation. During early diastole, which is linked  
345 to active relaxation of the LV, both AS and AR demonstrate ‘delayed’ relaxation. LV relaxation  
346 is affected by the LV diastolic untwisting rate, which in turn is affected by filling pressures,  
347 restoring forces (energy stored during systole) and thus systolic function (Nagueh *et al.*, 2016).  
348 Delayed or prolonged diastolic relaxation therefore is assumed to be the result of delayed and  
349 prolonged diastolic untwisting of the LV, which has been described before in chronic overload  
350 situations (Stuber *et al.*, 1999; Nagel *et al.*, 2000). A reduction of diastolic untwist is associated  
351 with attenuated or loss of the suction created by the LV and assumed to contribute to diastolic  
352 dysfunction (Nagueh *et al.*, 2009). Additional insights in the dissociation between the systolic  
353 and diastolic  $\epsilon$ -volume relation could therefore provide valuable insight in the shift in  
354 mechanics and haemodynamic changes that occur during chronic overload situations. Also  
355 during late diastole, associated with atrial contraction and chamber compliance, AS and AR  
356 show dissociation between the systolic and diastolic  $\epsilon$  for any given LV volume. Remodeling  
357 of the ventricles in AS and AR possibly contributes to an increase in passive stiffness and  
358 reduced chamber compliance (Aurigemma *et al.*, 2006; Dostal & Watson, 2006). Less  
359 compliant ventricles may show an impaired ability to alter  $\epsilon$  levels upon the return of ventricular  
360 volume. Due to these changes in early and late diastole, possibly as a result of structural  
361 remodeling, a rightward shift is present in the  $\epsilon$ -volume relationship during diastole. Although  
362 the underlying mechanisms are unclear, the presence of uncoupling between the systolic and  
363 diastolic  $\epsilon$ -volume relationship in AS and AR provide further evidence for a significant impact  
364 of both valve pathologies on LV function, which are not simply detected by current methods.

365

366 To explore the (clinical) value of the  $\epsilon$ -volume loop, we compared the ROC-curves for LVEF,  
367 longitudinal peak  $\epsilon$  and the combined loop characteristics between all groups. Whilst no (for  
368 LVEF) or limited (for peak  $\epsilon$ ) discriminative capacity was found for current techniques between  
369 the 3 groups, the novel loop characteristics provided strong, significant discriminative capacity  
370 between all groups. Additionally, we have compared overlap in these measures of the  $\epsilon$ -volume  
371 loop across the 3 groups. Remarkably, significant overlap is present for longitudinal peak  $\epsilon$   
372 across groups, highlighting the limited ability for longitudinal peak  $\epsilon$  to distinguish between  
373 groups. In contrast, marginal overlap is present between groups when comparing  $\epsilon_{ES}$  and  
374  $S_{slope}$  (Figure 3A-B), whilst also  $\epsilon_{ES}$  and  $S_{slope}$  show limited overlap between groups. To  
375 further support the potential discriminative capacity of the  $\epsilon$ -volume loop, we have compared  
376  $\epsilon$ -volume loops between subgroups of controls (n=3), AS (n=3) and AR (n=3) who demonstrate  
377 comparable longitudinal peak  $\epsilon$  (and LVEF). The different loop characteristics between groups  
378 highlight the potential clinical value of presenting  $\epsilon$ -volume loops when comparing cardiac  
379 function between groups.

380

381 *Clinical implication.* LVEF and longitudinal peak  $\epsilon$  provide limited insight and thus impact  
382 upon clinical decision making in AS and AR. The marked differences in  $\epsilon$ -volume loop  
383 characteristics across the 3 groups, even in the presence of preserved peak  $\epsilon$ , highlight the  
384 potential value of the  $\epsilon$ -volume loop. These observations, including the strong ROC-curves that  
385 support the discriminative capacity of  $\epsilon$ -volume loop characteristics, reinforce early suggestions  
386 from Gibson *et al.* who showed the usefulness of combining echocardiographic estimates of  
387 LV wall displacement and volume to assess temporal information of LV function (Gibson &  
388 Brown, 1973, 1974). Given the non-invasive character, use of traditional echocardiography  
389 protocols, and improved ability to discriminate between the variable load challenges in valve



390 pathology, this technique may be useful for relevant physiological insights in specific disease  
391 states and/or prognosis. Follow-up studies should therefore examine the clinical and prognostic  
392 value of the  $\epsilon$ -volume loop more extensively and consider the diagnostic and prognostic value  
393 of the loop characteristics over longitudinal peak  $\epsilon$ .

394

395 *Limitations.* Due to contemporary technological difficulties, we could only calculate and  
396 present longitudinal  $\epsilon$ -volume loops. Whilst the application to circumferential, radial and twist  
397 is feasible, concomitant volumes cannot be derived using contemporary 2D-techniques. Whilst  
398 3D-imaging potentially provides simultaneous  $\epsilon$  and volume in all planes, temporal resolution  
399 of current 3D-techniques provide too low frame rates ( $\pm 10$  fps) for valid assessment of  $\epsilon$ -volume  
400 loops. Currently applied methods are time-consuming taking up to 30 min per subject to acquire  
401 the  $\epsilon$ -volume loops. Automated temporal LV volume tracking would improve efficiency and  
402 feasibility to apply this method in daily clinical practice.

403

404 In conclusion, this exploratory study reinforces the marked structural remodeling observed in  
405 AS and AR and the presence of preserved LVEF as well as the attenuation of longitudinal  $\epsilon$  in  
406 both valve pathologies. Our novel measure of the temporal changes in the  $\epsilon$ -volume  
407 characteristics of the LV provides further insight into the haemodynamic cardiac impact of AS  
408 and AR, and is even able to distinguish between the impact of AS (i.e. increased afterload) and  
409 AR (i.e. increased volume overload). Therefore, this paper, using the  $\epsilon$ -volume relationship,  
410 provides novel insight in the functional and mechanical haemodynamic consequences of AS  
411 and AR, but also demonstrates improved ability (compared to traditional echocardiographic  
412 measures) to distinguish between the functional consequences of AS *versus* AR on LV function.

413 **Additional information**

414

415 **Disclosures**

416 None

417

418 **Author Contributions**

419 Experiments were performed at the departments of Physiology and Cardiology of the Radboud  
420 University Medical Center in Nijmegen. The conception and design of the work were carried  
421 out by all authors, acquisition, analysis and interpretation of the Data were performed by DT,  
422 DO, AvD and HH. All authors contributed in drafting or critically revising the manuscript. All  
423 authors approved the final version of this manuscript and agreed to be accountable for all  
424 aspects of the work. All persons designated as authors qualify for authorship and all those who  
425 qualify for authorship are listed.

426

427

428 **Sources of Funding**

429 This study was supported by a junior researcher grant from the Radboud Institute for Health  
430 Sciences

431

432 **Acknowledgements**

433 None

434 **REFERENCES**

- 435 Adda J, Mielot C, Giorgi R, Cransac F, Zirphile X, Donal E, Sportouch-Dukhan C, Reant P,  
436 Laffitte S, Cade S, Le Dolley Y, Thuny F, Touboul N, Lavoute C, Avierinos JF,  
437 Lancellotti P & Habib G. (2012). Low-flow, low-gradient severe aortic stenosis despite  
438 normal ejection fraction is associated with severe left ventricular dysfunction as  
439 assessed by speckle-tracking echocardiography: a multicenter study. *Circ Cardiovasc*  
440 *Imaging* **5**, 27-35.
- 441
- 442 Artis NJ, Oxborough DL, Williams G, Pepper CB & Tan LB. (2008). Two-dimensional strain  
443 imaging: a new echocardiographic advance with research and clinical applications. *Int*  
444 *J Cardiol* **123**, 240-248.
- 445
- 446 Aurigemma GP, Zile MR & Gaasch WH. (2006). Contractile behavior of the left ventricle in  
447 diastolic heart failure: with emphasis on regional systolic function. *Circulation* **113**,  
448 296-304.
- 449
- 450 Baumgartner H, Hung J, Bermejo J, Chambers JB, Evangelista A, Griffin BP, Iung B, Otto CM,  
451 Pellikka PA, Quinones M, American Society of E & European Association of E. (2009).  
452 Echocardiographic assessment of valve stenosis: EAE/ASE recommendations for  
453 clinical practice. *J Am Soc Echocardiogr* **22**, 1-23; quiz 101-102.
- 454
- 455 Bonow RO, Carabello BA, Chatterjee K, de Leon AC, Jr., Faxon DP, Freed MD, Gaasch WH,  
456 Lytle BW, Nishimura RA, O'Gara PT, O'Rourke RA, Otto CM, Shah PM, Shanewise  
457 JS, Writing Committee M & American College of Cardiology/American Heart  
458 Association Task F. (2008). 2008 Focused update incorporated into the ACC/AHA 2006  
459 guidelines for the management of patients with valvular heart disease: a report of the  
460 American College of Cardiology/American Heart Association Task Force on Practice  
461 Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of  
462 Patients With Valvular Heart Disease): endorsed by the Society of Cardiovascular  
463 Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and  
464 Society of Thoracic Surgeons. *Circulation* **118**, e523-661.
- 465
- 466 Carabello BA. (2008). Aortic stenosis: a fatal disease with but a single cure. *JACC Cardiovasc*  
467 *Interv* **1**, 127-128.
- 468
- 469 Carasso S, Cohen O, Mutlak D, Adler Z, Lessick J, Aronson D, Reisner SA, Rakowski H,  
470 Bolotin G & Agmon Y. (2011). Relation of myocardial mechanics in severe aortic  
471 stenosis to left ventricular ejection fraction and response to aortic valve replacement.  
472 *Am J Cardiol* **107**, 1052-1057.
- 473
- 474 Dandel M, Lehmkuhl H, Knosalla C, Suramashvili N & Hetzer R. (2009). Strain and strain  
475 rate imaging by echocardiography - basic concepts and clinical applicability. *Curr*  
476 *Cardiol Rev* **5**, 133-148.
- 477
- 478 Delgado V, Tops LF, van Bommel RJ, van der Kley F, Marsan NA, Klautz RJ, Versteegh MI,  
479 Holman ER, Schalij MJ & Bax JJ. (2009). Strain analysis in patients with severe aortic  
480 stenosis and preserved left ventricular ejection fraction undergoing surgical valve  
481 replacement. *Eur Heart J* **30**, 3037-3047.
- 482

- 483 Dong SJ, Hees PS, Huang WM, Buffer SA, Jr., Weiss JL & Shapiro EP. (1999). Independent  
484 effects of preload, afterload, and contractility on left ventricular torsion. *Am J Physiol*  
485 **277**, H1053-1060.
- 486
- 487 Dostal DE & Watson LE. (2006). Understanding diastolic heart failure with preserved ejection  
488 fraction: choosing the right model. *Hypertension* **47**, 830-832.
- 489
- 490 Dujardin KS, Enriquez-Sarano M, Schaff HV, Bailey KR, Seward JB & Tajik AJ. (1999).  
491 Mortality and morbidity of aortic regurgitation in clinical practice. A long-term follow-  
492 up study. *Circulation* **99**, 1851-1857.
- 493
- 494 Galli E, Lancellotti P, Sengupta PP & Donal E. (2014). LV mechanics in mitral and aortic valve  
495 diseases: value of functional assessment beyond ejection fraction. *JACC Cardiovasc*  
496 *Imaging* **7**, 1151-1166.
- 497
- 498 Gibson DG & Brown D. (1973). Measurement of instantaneous left ventricular dimension and  
499 filling rate in man, using echocardiography. *Br Heart J* **35**, 1141-1149.
- 500
- 501 Gibson DG & Brown D. (1974). Use of echocardiography in the evaluation of left ventricular  
502 function. *Proc R Soc Med* **67**, 140-142.
- 503
- 504 Hachicha Z, Dumesnil JG, Bogaty P & Pibarot P. (2007). Paradoxical low-flow, low-gradient  
505 severe aortic stenosis despite preserved ejection fraction is associated with higher  
506 afterload and reduced survival. *Circulation* **115**, 2856-2864.
- 507
- 508 Hein S, Arnon E, Kostin S, Schonburg M, Elsasser A, Polyakova V, Bauer EP, Klovekorn WP  
509 & Schaper J. (2003). Progression from compensated hypertrophy to failure in the  
510 pressure-overloaded human heart: structural deterioration and compensatory  
511 mechanisms. *Circulation* **107**, 984-991.
- 512
- 513 Iida N, Seo Y, Ishizu T, Nakajima H, Atsumi A, Yamamoto M, Machino-Ohtsuka T, Kawamura  
514 R, Enomoto M, Kawakami Y & Aonuma K. (2012). Transmural compensation of  
515 myocardial deformation to preserve left ventricular ejection performance in chronic  
516 aortic regurgitation. *J Am Soc Echocardiogr* **25**, 620-628.
- 517
- 518 Kamperidis V, Delgado V, van Mieghem NM, Kappetein AP, Leon MB & Bax JJ. (2016).  
519 Diagnosis and management of aortic valve stenosis in patients with heart failure. *Eur J*  
520 *Heart Fail*.
- 521
- 522 Lancellotti P, Tribouilloy C, Hagendorff A, Moura L, Popescu BA, Agricola E, Monin JL,  
523 Pierard LA, Badano L, Zamorano JL & European Association of E. (2010). European  
524 Association of Echocardiography recommendations for the assessment of valvular  
525 regurgitation. Part 1: aortic and pulmonary regurgitation (native valve disease). *Eur J*  
526 *Echocardiogr* **11**, 223-244.
- 527
- 528 Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, Flachskampf FA, Foster  
529 E, Goldstein SA, Kuznetsova T, Lancellotti P, Muraru D, Picard MH, Rietzschel ER,  
530 Rudski L, Spencer KT, Tsang W & Voigt JU. (2015). Recommendations for cardiac  
531 chamber quantification by echocardiography in adults: an update from the American

532 Society of Echocardiography and the European Association of Cardiovascular Imaging.  
533 *Eur Heart J Cardiovasc Imaging* **16**, 233-270.  
534

535 Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, Picard MH, Roman  
536 MJ, Seward J, Shanewise J, Solomon S, Spencer KT, St John Sutton M, Stewart W,  
537 American Society of Echocardiography's N, Standards C, Task Force on Chamber Q,  
538 American College of Cardiology Echocardiography C, American Heart A & European  
539 Association of Echocardiography ESoC. (2006). Recommendations for chamber  
540 quantification. *Eur J Echocardiogr* **7**, 79-108.  
541

542 Lavine SJ & Al Balbissi KA. (2015). Reduced Longitudinal Function in Chronic Aortic  
543 Regurgitation. *J Cardiovasc Ultrasound* **23**, 219-227.  
544

545 Lord R, George K, Somauroo J, Stembridge M, Jain N, Hoffman MD, Shave R, Haddad F,  
546 Ashley E, Jones H & Oxborough D. (2016). Alterations in Cardiac Mechanics  
547 Following Ultra-Endurance Exercise: Insights from Left and Right Ventricular Area-  
548 Deformation Loops. *J Am Soc Echocardiogr* **29**, 879-887 e871.  
549

550 Maganti K, Rigolin VH, Sarano ME & Bonow RO. (2010). Valvular heart disease: diagnosis  
551 and management. *Mayo Clin Proc* **85**, 483-500.  
552

553 Mangano DT, Van Dyke DC & Ellis RJ. (1980). The effect of increasing preload on ventricular  
554 output and ejection in man. Limitations of the Frank-Starling Mechanism. *Circulation*  
555 **62**, 535-541.  
556

557 Mondillo S, Galderisi M, Mele D, Cameli M, Lomoriello VS, Zaca V, Ballo P, D'Andrea A,  
558 Muraru D, Losi M, Agricola E, D'Errico A, Buralli S, Sciomer S, Nistri S, Badano L &  
559 Echocardiography Study Group Of The Italian Society Of C. (2011). Speckle-tracking  
560 echocardiography: a new technique for assessing myocardial function. *J Ultrasound*  
561 *Med* **30**, 71-83.  
562

563 Nagel E, Stuber M, Burkhard B, Fischer SE, Scheidegger MB, Boesiger P & Hess OM. (2000).  
564 Cardiac rotation and relaxation in patients with aortic valve stenosis. *Eur Heart J* **21**,  
565 582-589.  
566

567 Nagueh SF, Appleton CP, Gillebert TC, Marino PN, Oh JK, Smiseth OA, Waggoner AD,  
568 Flachskampf FA, Pellikka PA & Evangelisa A. (2009). Recommendations for the  
569 evaluation of left ventricular diastolic function by echocardiography. *Eur J*  
570 *Echocardiogr* **10**, 165-193.  
571

572 Nagueh SF, Smiseth OA, Appleton CP, Byrd BF, 3rd, Dokainish H, Edvardsen T, Flachskampf  
573 FA, Gillebert TC, Klein AL, Lancellotti P, Marino P, Oh JK, Popescu BA & Waggoner  
574 AD. (2016). Recommendations for the Evaluation of Left Ventricular Diastolic  
575 Function by Echocardiography: An Update from the American Society of  
576 Echocardiography and the European Association of Cardiovascular Imaging. *J Am Soc*  
577 *Echocardiogr* **29**, 277-314.  
578

579 Oxborough D, Heemels A, Somauroo J, McClean G, Mistry P, Lord R, Utomi V, Jones N,  
580 Thijssen D, Sharma S, Osborne R, Sculthorpe N & George K. (2016). Left and right

581 ventricular longitudinal strain-volume/area relationships in elite athletes. *Int J*  
582 *Cardiovasc Imaging* **32**, 1199-1211.  
583

584 Rassi AN, Pibarot P & Elmariah S. (2014). Left ventricular remodelling in aortic stenosis. *Can*  
585 *J Cardiol* **30**, 1004-1011.  
586

587 Samad Z, Vora AN, Dunning A, Schulte PJ, Shaw LK, Al-Enezi F, Ersboll M, McGarrah RW,  
588 3rd, Vavalle JP, Shah SH, Kisslo J, Glower D, Harrison JK & Velazquez EJ. (2016).  
589 Aortic valve surgery and survival in patients with moderate or severe aortic stenosis and  
590 left ventricular dysfunction. *Eur Heart J*.  
591

592 Smedsrud MK, Pettersen E, Gjesdal O, Svennevig JL, Andersen K, Ihlen H & Edvardsen T.  
593 (2011). Detection of left ventricular dysfunction by global longitudinal systolic strain in  
594 patients with chronic aortic regurgitation. *J Am Soc Echocardiogr* **24**, 1253-1259.  
595

596 Stuber M, Scheidegger MB, Fischer SE, Nagel E, Steinemann F, Hess OM & Boesiger P.  
597 (1999). Alterations in the local myocardial motion pattern in patients suffering from  
598 pressure overload due to aortic stenosis. *Circulation* **100**, 361-368.  
599

600 Taniguchi K, Kawamaoto T, Kuki S, Masai T, Mitsuno M, Nakano S, Kawashima Y & Matsuda  
601 H. (2000). Left ventricular myocardial remodeling and contractile state in chronic aortic  
602 regurgitation. *Clin Cardiol* **23**, 608-614.  
603

604 Weidemann F, Herrmann S, Stork S, Niemann M, Frantz S, Lange V, Beer M, Gattenlohner S,  
605 Voelker W, Ertl G & Strotmann JM. (2009). Impact of myocardial fibrosis in patients  
606 with symptomatic severe aortic stenosis. *Circulation* **120**, 577-584.  
607  
608

609 **FIGURE AND TABLE LEGENDS**

610 **Figure 1** – A schematic view of the methods used to assess the  $\epsilon$ -volume loops. The black line  
611 represents the  $\epsilon$ -volume loop, the thick part represents the systolic phase and the thin line the  
612 diastolic phase. We assessed the  $\epsilon$ -volume loop by a) systolic  $\epsilon$  at 90% of EDV (i.e.  $\epsilon_{ES}$ ; red  
613 dotted line), b)  $\epsilon$ -volume relation across the systolic phase (i.e.  $S_{slope}$ , orange dashed line), c)  
614 peak  $\epsilon$  at end-systole (i.e. peak  $\epsilon$ ), d) difference in systolic vs diastolic  $\epsilon$  during early filling (i.e.  
615 UNCOUP\_ED) and e) difference in systolic vs diastolic  $\epsilon$  during atrial contraction (i.e.  
616 UNCOUP\_LD).

617

618 **Figure 2** – Data represents average longitudinal  $\epsilon$ -volume loops in controls (n=10, solid lines),  
619 aortic stenosis (AS, n=10, short dashed line) and aortic regurgitation (AR, n=7, long dashed  
620 lines). All data represents the mean value at the various time points.

621

622 **Figure 3** – Comparison between longitudinal peak  $\epsilon$  (Y-axis, in %) and  $\epsilon$ -volume loop  
623 characteristics  $S_{slope}$  (A),  $\epsilon_{ES}$  (B), UNCOUP\_ED (C) and UNCOUP\_LD (D) for controls  
624 (solid circle), AS (solid square) and AR (solid triangle). The grey areas represent the reference  
625 areas, based on data from the control group. Error bars represent SD. Note the large variation  
626 in longitudinal peak  $\epsilon$  that overlaps across groups, whilst smaller variation with less overlap is  
627 present for the  $\epsilon$ -volume loop characteristics.

628

629 **Figure 4** – Data represents average longitudinal  $\epsilon$ -volume loops in a subgroup of healthy  
630 controls (n=3, solid lines), aortic stenosis (AS, n=3, short dashed line) and aortic regurgitation  
631 (AR, n=3, long dashed lines) with comparable longitudinal peak  $\epsilon$ . Note the marked differences  
632 in  $\epsilon$ -volume loops characteristics between groups, despite comparable longitudinal peak  $\epsilon$ .

633 **Table 1** – Baseline demographics.

Baseline characteristics	Controls	Cardiac valve pathology		
		AS	AR	P-Value
Age (yrs)	50±10	47±11	45±10	0.539
Height (cm)	176±9	178±9	178±6	0.752
Weight (cm)	77±13	80±12	79±8	0.830
BSA (m <sup>2</sup> )	1.93±0.19	1.98±0.19	1.96±0.12	0.766
HR (bpm)	71±12	68±10	62±8	0.283
Female:male	5:5	4:6	1:6	0.315
<b>Echocardiographic</b>				
IVSd (cm)	0.8±0.2	1.1±0.2*	1.1±0.1*	<0.01
LVIDd (cm)	4.5±0.4	4.7±0.3 <sup>†</sup>	6.2±0.7* <sup>†</sup>	<0.01
LVPWd (cm)	0.9±0.2	1.1±0.2	1.2±0.1*	<b>0.04</b>
LVD Mass Index (g/m <sup>2</sup> )	65.7±12.7	92.0±15.3 <sup>†</sup>	177.2±57.1* <sup>†</sup>	<0.01
LVEDV (ml)	98±25	121±22 <sup>†</sup>	244±37* <sup>†</sup>	<0.01
LVESV (ml)	36±14	48±11 <sup>†</sup>	104±25* <sup>†</sup>	<0.01
LVEF (%)	62±7	60±4	58±4	0.32
SV (ml)	61±17	73±13 <sup>†</sup>	140±17* <sup>†</sup>	<0.01
CO (L/min)	4.2±0.7	5.0±1.5 <sup>†</sup>	8.7±1.5* <sup>†</sup>	<0.01
LAESV(ml)	37.1±9.9	46.1±11.1 <sup>†</sup>	68.1±35.0* <sup>†</sup>	<b>0.01</b>
LADiam (cm)	3.5±0.5	3.5±0.6	3.7±0.6	0.73
<b>AS specific</b>				
AVA (cm <sup>2</sup> )	-	0.8±0.1	-	-
Mean pressure gradient (mmHg)	-	50±13	-	-



Dimensionless Index	-	0.19±0.03	-	-
<b>AR specific</b>				
VC (mm)	-	-	8.3±1.2	-
ED Vmax (m/s)	-	-	0.26±0.07	-

---

634

635 Symbols denote P<0.05 to Controls=\* , between AS and AR=† (AS=Aortic stenosis; AR=Aortic  
636 regurgitation; BSA=Body surface area; HR=Heart rate; IVSd=Interventricular septal thickness  
637 at diastole; LVIDd=Left ventricle internal diameter at diastole; LVPWd=Left ventricle  
638 posterior wall at diastole; LVEDV=Left ventricle end diastolic volume; LVESV=Left ventricle  
639 end systolic volume; LVEF=Left ventricle ejection fraction; SV=Stroke volume; CO=Cardiac  
640 output; LAESV=Left ventricle end systolic volume; LADiam=Left atrial diameter;  
641 AVA=Aortic Valve Area; VC = Vena contracta; ED Vmax = End diastolic velocity)

642

643 **Table 2** – Characteristics derived from  $\epsilon$ -volume loop.

Longitudinal $\epsilon$ -volume loop	Controls	Cardiac pathology		P-Value
		AS	AR	
$\epsilon_{ES}(\%)$	-2.5±1.1 (-4.3;-1.4)	-1.4±0.9* <sup>†</sup> (-3.0;-0.4)	-0.1±1.1* <sup>†</sup> (-2.2;1.0)	<b>&lt;0.01</b>
Sslope (%/ml)	-0.35±0.05 (-0.44;-0.28)	-0.26±0.07* <sup>†</sup> (-0.37;-0.16)	-0.11±0.02* <sup>†</sup> (-0.14;-0.07)	<b>&lt;0.01</b>
Peak $\epsilon$ (%)	-19.6±3.7 (-28.4;-15.8)	-16.7±1.3* (-18.2;-14.0)	-15.0±1.9* (-18.4;-12.7)	<b>&lt;0.01</b>
UNCOUP_ED	-3.6±5.0 (-11.5;6.2)	3.1±6.2* (-8.4;13.9)	5.5±5.1* (-2.7;12.1)	<b>&lt;0.01</b>
UNCOUP_LD	-0.3±3.3 (-4.4;6.0)	3.9±3.8* (-0.4;12.6)	4.7±4.4* (-2.4;9.9)	<b>0.02</b>

644 Symbols denote P<0.05 to Controls=\* , between AS and AR=<sup>†</sup> (AS=Aortic stenosis; AR=Aortic  
645 regurgitation)